Development of a Probiotic Strategy to Prevent or Eliminate Nasal Colonization With S. Aureus

Sponsor
Tufts Medical Center (Other)
Overall Status
Withdrawn
CT.gov ID
NCT00977496
Collaborator
(none)
0

Study Details

Study Description

Brief Summary

The goal of this study is characterize the changes in bacterial diversity of the nares of hemodialysis patients. Another goal is to determine when hemodialysis patients become colonized with the bacteria Staphylococcus aureus, as nasal colonization with S. aureus is a major risk factor for invasive infection in hemodialysis patients. Fifteen subjects will be recruited into the study. Nasal swabs will be collected every month for six months or until one month after S. aureus colonization in order to determine any changes in the bacterial communities of the nose. Clinical data will also be collected to evaluate the possible influence of external factors on changes in the microbial communities in the patients' noses. This study will provide preliminary data on whether oral- and/or nasal-administered probiotics can eliminate nasal carriage of S. aureus.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Nasal Swab

Study Design

Study Type:
Observational
Actual Enrollment :
0 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Development of a Probiotic Strategy to Prevent or Eliminate Nasal Colonization With S Aureus
Study Start Date :
May 1, 2011

Arms and Interventions

Arm Intervention/Treatment
Nasal Swab

New chronic hemodialysis patients with no evidence of nasal carriage of Staphylococcus aureus from Boston Dialysis Center Inc., the outpatient hemodialysis clinic of Tufts Medical Center

Procedure: Nasal Swab
Swabs will be moistened in sterile 0.9% sodium chloride solution and rotated in the anterior vestibule of both nares and processed for S aureus cultures and for bacterial DNA extraction.

Outcome Measures

Primary Outcome Measures

  1. To describe the clinical variables that may be associated with the acquisition of S aureus nasal colonization, over a six-month period. [Monthly for 6 months or monthly until 1 month after positive nasal swab for S aureus]

  2. To refine and test the feasibility of using non culture-based methods to study the microbial ecology and bacterial diversity of the anterior nares in patients starting hemodialysis using 16sRNA sequence analysis. [Monthly for 6 months or monthly until 1 month after positive nasal swab for S aureus]

  3. To explore changes in bacterial diversity in the anterior nares over a six-month period and in conjunction with S aureus colonization. [Monthly for 6 months or monthly until 1 month after positive nasal swab for S aureus]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Male and female subjects aged 18 years or older

  • On a stable hemodialysis schedule three times a week at Tufts Medical Center outpatient hemodialysis unit

  • Able to speak English, Spanish, Cantonese, or Mandarin (One of these languages is spoken by >95% of our hemodialysis population)

  • Provides informed consent to participate in the study

  • No plans to be absent from the dialysis unit in the next 6 months

  • Willingness to report on adverse events during the study period

Exclusion Criteria:
  • Patients in which hemodialysis was indicated for acute renal failure secondary to septic shock, acute tubular necrosis, or other condition which is felt to be temporary or secondary to a life threatening illness or likelihood of hemodialysis for less than 6 months.

  • Treatment with systemic anti-staphylococcal antibiotic therapy within 30 days prior to enrollment or planned use of topical mupirocin applied to the nares

  • Receiving peritoneal dialysis (concordance between the colonizing and infecting strain is not as high as in the hemodialysis population (105))

  • Absolute neutrophil count less than 500/mm3 or anticipated fall in neutrophil count < 500/mm3 (e.g. as a result of recent chemotherapy)

  • Bleeding diathesis such as platelets count less than 20 or INR >4 within the last 30 days

  • On immunosuppressive therapy

  • Anticipated renal transplant during the next 6 months

  • Evidence of active bowel leak, acute abdomen or colitis

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Tufts Medical Center

Investigators

  • Principal Investigator: Patricia L Hibberd, MD, PhD, Tufts Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00977496
Other Study ID Numbers:
  • 8784
First Posted:
Sep 15, 2009
Last Update Posted:
Mar 18, 2015
Last Verified:
Mar 1, 2015
Keywords provided by , ,

Study Results

No Results Posted as of Mar 18, 2015